Katja Harbst

Katja Harbst

Lund, M, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

SWE-NEO: Swedish NEO-adjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4/anti-PD-1 blockade in resectable stage III melanoma: study protocol for a phase III open-label multi-centre trial.

SWE-NEO: Swedish NEO-adjuvant trial comparing anti-PD-1 monotherapy to combined anti-CTLA-4/anti-PD-1 blockade in resectable stage III melanoma: study protocol for a phase III open-label multi-centre trial.

Journal: Acta oncologica (Stockholm, Sweden)
Published: December 17, 2025

Modeling anti-tumor immune responses using patient-derived melanoma organoids.

Modeling anti-tumor immune responses using patient-derived melanoma organoids.

Journal: Cancer immunology, immunotherapy : CII
Published: August 29, 2025

Pericytes orchestrate a tumor-restraining microenvironment in glioblastoma.

Pericytes orchestrate a tumor-restraining microenvironment in glioblastoma.

Journal: Nature communications
Published: September 24, 2024

BioMEL: a translational research biobank of melanocytic lesions and melanoma.

BioMEL: a translational research biobank of melanocytic lesions and melanoma.

Journal: BMJ open
Published: February 03, 2024

Characterization of somatic mutations in sporadic uveal melanoma and uveal melanoma in patients with germline BAP1 pathogenic variants.

Characterization of somatic mutations in sporadic uveal melanoma and uveal melanoma in patients with germline BAP1 pathogenic variants.

Journal: PloS one
Published: December 19, 2023

Molecular patterns of resistance to immune checkpoint blockade in melanoma.

Molecular patterns of resistance to immune checkpoint blockade in melanoma.

Journal: Nature communications
Published: July 27, 2023

DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype.

DNA promoter hypermethylation of melanocyte lineage genes determines melanoma phenotype.

Journal: JCI insight
Published: November 22, 2021

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma.

Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma.

Journal: Journal for immunotherapy of cancer
Published: May 28, 2021

Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens.

Rapid Identification of the Tumor-Specific Reactive TIL Repertoire via Combined Detection of CD137, TNF, and IFNγ, Following Recognition of Autologous Tumor-Antigens.

Journal: Frontiers in immunology
Published: May 05, 2021

Transcriptomic signatures of tumors undergoing T cell attack.

Transcriptomic signatures of tumors undergoing T cell attack.

Journal: Cancer immunology, immunotherapy : CII
Published: April 01, 2021

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.

Journal: Breast cancer research : BCR
Published: November 16, 2020

Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma.

Qualitative Analysis of Tumor-Infiltrating Lymphocytes across Human Tumor Types Reveals a Higher Proportion of Bystander CD8+ T Cells in Non-Melanoma Cancers Compared to Melanoma.

Journal: Cancers
Published: October 07, 2020
Showing 1-12 of 33

Last Updated: 09/26/2026